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Neuropeptide immunohistochemistry was used to test several hypotheses of the anatomical bases of chorea and 
rigidity-kinesia. To  test the hypothesis that elevated concentration of striatal somatostatin causes chorea, we visually 
compared the density of striatal neurons containing somatostatin and neuropeptide Y in brains affected by choreic or 
rigid-kinetic Huntington's disease (HD). The density of these neurons was elevated in both rigid-kinetic and choreic 
HD specimens with an apparently normal total number of these neurons, indicating that elevated somatostatin concen- 
tration, by itself, does not lead to chorea. We tested the hypothesis that rigid-kinetic HD results from deficient 
dopaminergic nigrostriatal neurotransmission by examining tyrosine hydroxylase-immunoreactive (TH-IR) neurons 
in the substantia nigra. In rigid-akinetic HD brains, there was no obvious reduction of nigral TH-IR neurons, 
indicating that rigid-akinetic HD is probably not due to loss of nigral dopaminergic neurons. Finally, we also exam- 
ined the status of striatal projection neurons and found near total loss of all striatal neurons projecting to the lateral 
globus pallidus, medial globus pallidus, and substantia nigra in brains affected by rigid-kinetic HD in contrast to the 
preservation of neurons projecting to the medial globus pallidus in choreic HD. These results are consistent with the 
hypothesis that chorea results from preferential loss of striatal neurons projecting to the lateral globus pallidus and 
that rigid-kinetic HD is a consequence of the additional loss of striatal neurons projecting to the medial segment of 
the pallidum. 
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An undemanding of the mechanisms underlying cho- 
rea has long eluded neurologists. While chorea is asso- 
ciated with striatal pathology, efforts to produce chorea 
in animals by creating striatal lesions have been unsuc- 
cessful [l-31. Similarly, traumatic or vascular lesions 
of the striatum in humans do not generally cause chorea 
14, 51. This apparent paradox has led to speculation 
that chorea may result from the preferential loss of 
specific subpopulations of striatal neurons, with selective 
preservation of other striatal neuron subpopulations 
C6, 71. 
Along these lines, one recent hypothesis regarding 
chorea is that it results from a relative excess of so- 
matostatin (SS) in the striatum 161. This idea derives 
from the observation that stria@ interneurons contain- 
ing both SS and neuropeptide Y (NPY) are spared in 
Huntington's disease (HD) [S, 91. The resulting rela- 
tive increase in the concentration of striatal SS is 
thought to influence the action of dopamine in the 
striatum. SS enhances dopamine release by nigrostri- 
atal terminals and may potentiate the effect of dopamine 
on striatal neurons [10-121. Intrastriatal injection of 
SS agonists in rats produces stereotypical behavior sim- 
ilar to that seen with the administration of dopamine 
agonists [l2). 
An alternative hypothesis is that chorea results from 
selective degeneration of striatal neurons projecting to 
the external globus pallidus (GPe) with preservation 
of neurons projecting to the internal globus pallidus 
(GPi) [I, 7). This hypothesis is supported by the re- 
cent discovery of preferential loss of striatal neurons 
projecting to the GPe in the early stages of HD {13) 
and by the development of a nonhuman primate 
model of chorea in which hyperhnetic dyskinesias are 
From the *Department of Neurology, University of Michigan, Ann 
Arbor, MI, and the tDepartment of Anatomy and Neurobiology, 
University of Tennessee Health Science Center, Memphis, TN. 
Received Jul 10, 1989, and in revised form Sep 21. Accepted for 
publication Sep 22, 1989. 
Address correspondence to Dr Albin, Neuroscience Laboratory 
Building, 1103 E. Huron, Ann Arbor, MI 48104. 
Copyright 0 1990 by the American Neurological Association 357 
Table 1 .  Clinical Characteristics and Postmortem Specimen Characteristics of Rigid HD CaseJ 
Age at Postmortem Fixation 
Case No. Sex Death (yr) Grade Delay (hr) Time Symptoms Medications 
1 F 31 4 24 24 mo Rigidity, bradykinesia, 
juvenile-onset 




3 F 20 4 18 16 mo Dementia, rigidity, 
4 F 34 3 ? 6 mo Rigidity, adult-onset 









induced by pharmacological blockade of striatal input 
to the GPe {14]. 
To evaluate these hypotheses we used immunohis- 
tochemistry to determine the status of striatal inter- 
neurons containing SS and NPY and striatal neuropep- 
tide-containing projection neurons in 4 cases of rigid- 
akinetic HD. This unusual variant of HD, in which the 
presentation and clinical course are dominated by 
rigidity and bradykinesia rather than chorea, offers an 
opportunity to test theories of chorea. If SS excess is 
the sole cause of chorea, then one would expect that 
brains affected by rigid-akinetic HD, which lack cho- 
rea, should not exhibit the sparing of striatal neurons 
containing SS and NPY seen in HD. Conversely, if 
selective degeneration of striatal neurons projecting to 
the GPe with sparing of those projecting to the GPi is 
the cause of chorea, then one would predict that speci- 
mens from patients with rigid HD should not exhibit 
the selective loss of striatal neurons projecting to the 
GPe and should exhibit a different pattern of loss of 
striatal projection neurons. 
In addition, we evaluated also the status of striatal 
neurons projecting to the substantia nigra (SN) and 
tyrosine hydroxylase-containing neurons in the SN. 
The latter are of particular interest because Stoessel 
and colleagues suggested that the rigidity sometimes 
seen in HD is a result of deficient nigrostriatal trans- 
mission [ 151. 
Methods 
Patient Material 
We studied specimens from 4 cases of rigid-akinetic HD 
(Table 1). Three of the 4 cases had onset before the age of 
20 (juvenile onset), and 1 had onset in the early twenties 
(early adult onset). All had a clinical course dominated by 
rigidity and bradykinesia with little or no chorea (see Table 1 
for clinical characteristics). All specimens were pathologically 
graded according to the criteria of Vonsattel and associates 
1161. All specimens from cases of juvenile-onset HD were 
grade 4, while the specimen from the one with adult-onset 
HD was grade 3. One specimen was obtained from the 
Pathology Department at the University of Michigan Med- 
ical Center, 1 from the Pathology Department of Stanford 
University, and 2 from the Brain Tissue Resources Center 
(BTRC; Belmont, MA). Brains were obtained at autopsy and 
were fixed in either unbuffered 15% formalin (University of 
Michigan and Stanford University) or 10% neutral buffered 
formalin (BTRC). The average postmortem delay prior to 
fixation was 17 hours. After 2 to 3 weeks of fixation, the 
brains were blocked and stored in 10 to 15% formalin 0.1 M 
phosphate buffer (PB; pH 7.4). The average duration of 
fixation was 12 months. We also examined specimens from a 
previously described group of patients with choreic HD and 
previously described neurologically normal and abnormal 
control subjects [13}. Both the rigid-akinetic and choreic 
specimens described here were used in our previous study 
of striatal projection neurons in HD El31 but extensive 
clinicopathological correlations were not attempted in that 
study. For comparison with the cases of rigid HD we used 4 
specimens of well-documented choreic HD. The average age 
at death of the patients who had choreic HD was 49 years 
(range, 19-81 years); the average postmortem delay was 
12.5 hours (range, 2-24 hours); the average duration of 
fixation was 12.1 months (range, 0.5-18 months); and the 
specimens were grades 2 or 3. Of the choreic group 1 had 
juvenile-onset HD (age 19 at death) with grade 3 pathology. 
For control specimens (total number = 13), the average age 
at death was 56 years (range, 10-81 years); the average post- 
mortem delay was 13 hours (range, 5-26 hours); and the 
average duration of fixation was 9.6 months (range, 0-21 
months). The controls included specimens from children and 
young adults (ages 10, 15, 27, and 34 years). The results 
from specimens in these younger subjects were identical to 
those obtained in older adults. 
Immunobistocbemi~t~ 
Tissue blocks containing putamen and pallidurn or SN were 
recovered from formalin and immersed in 20% sucrose 10% 
glycerol PB containing 0.01% sodium azide at 4°C until the 
time of assay. Forty-micron-thick frozen sections were cut 
on a sliding microtome and immunohistochemistry was per- 
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formed using the peroxidase-antiperoxidase technique as 
previously described [ 131. To examine striatal interneurons 
containing SS and NPY we used several well-characterized 
and highly specific primary antisera directed against SS 
(INCstar Inc, Stillwater, MN; dilution 1 : 500; and gift of 
Drs S. Vincent and J. Brown, dilution 1 : 500) [17] and NPY 
(gift of Dr J. Polak, dilution 1:500; and gift of Drs J. R. 
Oliver and W. Blessing, dilution 1:500 f18, 191. The 
integrity of striatal projection neurons was assessed by visu- 
alization of enkephalin-immunoreactive nerve terminals in 
the GPe, and substance P-immunoreactive nerve terminals 
in the GPi and SN. Changes in the abundance of labeled 
terminals were used to infer changes in the density of striatal 
neurons projecting to the GPe, GPi, and SN. We used well- 
characterized antisera directed against substance P (Accurate 
Chemical and Scientific, Westbury, NY; dilution 1 : 2,000), 
[Leu]-enkephalin (INCstar, dilution 1 : 1,000) and [Met]- 
enkephalin-Arg6-Gly7-Leu8 (gift of Dr G. J. Dockray, dilu- 
tion 1:500). The latter two antisera both stain enkeph- 
alinergic nerve terminals and produce identical staining 
patterns [l 31. Dopaminergic nigral neurons and neuropil 
were visualized using a highly specific antiserum directed 
against tyrosine hydroxylase (Eugenetech, Allandale, NJ; di- 
lution 1 :4,000). Sections were viewed under bright field 
illumination and the changes in neuropeptide-containing 
perikarya and nerve terminals and tyrosine hydroxylase- 
Containing perikarya were qualitatively assessed by compari- 
son with control and choreic HD specimens. In 1 case of 
juvenile-onset rigid HD (Case l), a pediatric control case 
(age lo), and a case of juvenile-onset choreic HD, sections 
were taken at equivalent levels of the putaminopallidal com- 
plex and the distribution of striatal neurons containing SS 
and NPY was charted using a camera lucida technique. 
Results 
Striatal Interneurons Containing SS and NPY 
The striatal neurons containing SS and NPY were 
readily visualized in all specimens (Fig 1). As with 
choreic HD specimens, the areal density of these inter- 
neurons in the atrophied putamen of all rigid speci- 
mens appeared elevated compared with control speci- 
mens (Table 2). Charting and subsequent counting of 
neurons containing SS and NPY in 1 case of rigid HD, 
1 choreic case, and a pediatric control case revealed no 
evident difference in the number of NPY-immuno- 
reactive neurons between these specimens (Fig 2). 
Peptidergic Striatal Projection Neuron Terminals 
In the control specimens, there was robust staining of 
enkephahnergic terminals in the GPe and substance 
P-containing terminals in the GPi and SN (see Table 
2, Figs 3 and 4). In all grade 4 rigid cases there was 
near total depletion of peptidergic terminals in the 
GPe, GPi, and SN, indicating near total depletion of 
the striatal projection neurons giving rise to these ter- 
minals. In the one grade 3 rigid-akinetic specimen, 
there was substantial loss of enkephalin immunoreac- 
tivity in the GPe and a somewhat lesser loss of sub- 
stance P immunoreactivity in the GPi (see Table 2). 
Substance P immunoreactivity in SN was markedly 
depleted in this specimen. In the grade 3, juvenile- 
onset choreic specimen and in other choreic speci- 
mens, there was substantial sparing of substance P im- 
munoreactivity in the GPi and great loss of enkephahn 
immunoreactivity in the GPe (see Fig 4). 
Tyrosine Hydroxylase Immunoreactivity in the SN 
In all specimens there was a normal distribution and 
abundance of tyrosine hydroxylase-immunoreactive 
neuropils and neurons in the SN (Fig 5). 
Discussion 
We used immunohistochemistry to evaluate the status 
of striatal and nigral neuron subpopulations in rigid 
HD. Striatal interneurons containing SS and NPY and 
nigral neurons containing tyrosine hydroxylase were 
directly visualized, and the density of striatal projec- 
tion neurons was indirectly assessed by visualization of 
neuropeptide-containing terminals in the GPe, GPi, 
and SN. This latter approach is necessary because it is 
difficult to visualize the perikarya of striatal projection 
neurons without intraventricular colchicine treatment, 
a technique not applicable to humans. The majority of 
striatal projection neurons send their efferents to only 
one target region 120-221, and can also be differ- 
entiated by which neuropeptide they contain. Striatal 
neurons projecting to the GPe contain enkephahns, 
while striatal neurons projecting to the GPi and SN 
contain substance P 123, 241. Consequently, it is possi- 
ble to examine the density of neuropeptide-immuno- 
reactive terminals in the GPe, GPi, and SN and make 
reliable inferences about the integrity of subpopula- 
tions of striatal projection neurons giving rise to those 
terminals. We assume that loss of immunoreactivity in 
the terminal fields is the result of striatal neuron de- 
generation but we cannot exclude the possibility that 
loss of neuropeptide immunoreactivity in the terminal 
fields represents dysfunction of striatal neurons rather 
than degeneration. 
Our results are inconsistent with the hypothesis that 
elevated striatal concentrations of SS are the sole cause 
of chorea. In all specimens of rigid HD, we found appar- 
ently complete preservation of striatal interneurons 
containing SS and NPY, indicating that another mech- 
anism is responsible for chorea. This conclusion is sup- 
ported by the results of a clinical trial in which cys- 
teamine, an agent known to deplete central nervous 
system SS, was administered to patients with choreic 
HD [251. N o  amelioration of chorea was seen. Ex- 
perimental data also support the conclusion that ele- 
vated striatal concentration of SS is not the cause of 
chorea. Leblanc and associates recently reported the 
results of intrathecal infusion of SS agonists in nonhu- 
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Fig  I. Striatal neurons immunohistochemically labeled for 
neuropeptide Y (NPY). (A) The putamen of a normal juvenile. 
(B) The putamen from a case of choreic juvenile-onset H D  (grade 
3). (C) The putamen from a case of rigid adult-onset H D  (Case 
4,  grade 3). (0) The caudate from a case of rigid juvenile-onset 
H D  (Case 3, grade 4). Scale bar = 100 pm. 
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Table 2. Summary of lmmunohistochemical Findings in Rigid H D  Specimens 
Case No. Put SS-IR Put NPY-IR GPe ENK-IR GPi  SP-IR SN SP-IR SN TH-IR 
1 t t  t t  1 1 1  1 J 1  1 1 1  Normal 
2 t t  t t  111  -144 1 1 1  Normal  
3 t t  t t  1 1 1  1 1 1  1 1 5  Normal 
4 t t  t t  1 1 1  5 1  5 1  Normal  
Put = putamen; GPe = external globus pallidus; GPi = internal globus pallidus; SN = substantia nigra; SS-IR = somatostatin- 
immunoreactive; NPY-IR = neuropeptide Y-immunoreactive; ENK-IR = enkephalin-immunoreactive; SP-IR = substance P- 
immunoreactive; TH-IR = tyrosine hydroxylase-immunoreactive; t t = markedly increased density of immunoreactive perikarya; .1 .1 J. = 
near total depletion of immunoreactive terminals; .1 .1 = markedly decreased density of immunoreactive terminals. 
man primates [261. They observed bradykinesia in ani- 
mals receiving chronic infusion of the long-acting SS 
agonist SMS 201-995, which indicates that in primates 
in vivo, the SS agonist elicits effects similar to those 
induced by dopamine antagonists. Consistent with this 
hypothesis, the bradykinesia was reversed by adminis- 
tration of the dopamine agonist apomorphine. The re- 
sults of Leblanc and associates directly contradict the 
idea that SS potentiates the effect of dopamine in the 
striatum in primates and that chorea results from ex- 
cess striatal SS. Their results are also inconsistent with 
data obtained in rodents and suggest the existence of 
an interspecies difference between primates and rats in 
the effect of SS in the striatum. 
Our results are consistent with the hypothesis that 
chorea results from selective loss of striatal neurons 
projecting to the GPe. In a previous study, we found 
that grade 2 and some grade 3 HD specimens are 
marked by selective loss of neurons projecting to the 
GPe. In some of the cases studied in that report there 
was enough clinical information available to correlate 
the selective loss of neurons projecting to the GPe 
with the presence of chorea [13]. In the rigid-akinetic 
grade 3 and 4 specimens reported in the present study, 
we found evidence of profound loss of striatal neurons 
projecting to the GPe, GPi, and SN. This nonselective 
loss of striatal projection neurons correlates with the 
rigidity and lack of chorea exhibited by the patients. 
Our analysis of these rigid-akinetic cases does not, 
however, constitute a definitive test of the hypothesis 
that chorea results from selective loss of striatal neu- 
rons projecting to the GPe, because we were able to 
examine only specimens from cases with grade 3 and 4 
rigid HD. It is still possible that selective loss of striatal 
projections to the GPe might be observed in earlier 
grades of rigid-akmetic HD. A better test of the hy- 
pothesis would be to evaluate cases of rigid-akinetic 
HD at earlier grades of HD and to compare early- 
grade rigid HD with early-grade choreic HD. 
The hypothesis that chorea results from selective 
loss of striatal neurons projecting to the GPe and that 
rigidity-akinesia is associated with loss of striatal neu- 
rons projecting to both the GPe and GPi implies that 
F i g  2. Camera lucida reconstructions of the distributions of 
neuropeptide Y-immunoreactiwe (NPY +) neurons at com- 
parable levels of the basal ganglia. (A) A normal juvenile. 
(B) Choreic juvenile-onset H D  (grade 3). (C) Rigid juwenile- 
onset H D  (Case 3 ,  grade 4). Although the number of NFY- 
immunoreactive perikarya is similar, shrinkage of the putamen 
greatly elevates the packing density of these neurons in grade 3 
and 4 HD. GFe = external globus paallidus; GPi = internal 
globus palliduls. 






Fig 3. Low-power photomicrographs, comparing enkephalin- 
immunoreactive (ENK) fiber labeling in  external globus pallidus 
(GPe), substance P-immunoreactive (SP) fiber labeling in  inter- 
nal globus pallidus (GPi), and substance P-immunoreactive 
jiber labeling in substantia nigra (SN) in a normal individual 
with that observed in a brain specimen of rigid, grade 4 
juvenile-onset H D  (Case 1). Note the depletion offiber abun- 
dance in GPe, GPi, and SN in the H D  specimens. Scale bar = 
5 mm. 
early in the course of HD, patients with rigid HD 
should have a greater degree of neuronal depletion in 
the striatum than those with choreic HD. This predic- 
tion is consistent with the observation that juvenile- 
onset HD, which has an enriched percentage of rigid 
cases {27, 281, has a more rapid and severe degenera- 
tive course {291. A recent positron emission tomog- 
raphy (PET) study of patients with juvenile-onset HD 
showed that they had a greater degree of caudate 
hypometabolism when compared with patients with 
adult-onset HD of similar functional capacity 1301; this 
suggests that juvenile-onset HD involves a greater de- 
gree of striatal cell loss early in the course of the dis- 
ease than typical adult-onset HD. 
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Fig 4. High-pwwer photomicrographs comparing enkephalin- 
immunoreactive (ENK) fiber labeling in external globus pallidus 
(A) and substance P-immunoreactive (SP) fiber labeling in in- 
ternal globus pallidus (B) in a normal juvenile to that observed 
(C and D) in a case of choreic juvenile-onset HD (grade 3) and 
to that observed (E and F )  in a case of rigid juvenile-onset HD 
(Case 3, grade 4). Note the relative preservation of substance P 
fibers in the internal globus pallidus of the choreic HD specimen, 
while both substance P and enkephalin fibers in the internal 
globus pallidus and external globus pallidus, respectively, are 
largely absent in the case of rigid HD. Scale bar = 50 pm. 
N = normal; C = choreic; R = rigid. 
Stoessel and colleagues suggested that the rigidity of 
juvenile-onset HD might be secondary to deficient 
nigrostriatal dopaminergic neurotransmission 11 57. Our 
finding of normal tyrosine hydroxylase immunoreac- 
tivity in the SN in these brain specimens of rigid HD 
indicates that there is no great loss of nigrostriatal pro- 
jection neurons. Immunohistochemistry cannot assess 
functional activity and our results do not exclude an 
abnormality of dopamine metabolism in the striatum, 
perhaps due to loss of striatal afferents to SN. Spokes, 
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Fig 5 .  High-power photomicrographs showing that the abun- 
h n c e  of tyrosine hydroxylase-immunoreactiue perika y a  in  the 
substantia nigra of a brain specimen of choreic H D  (A) is no 
d;ffevent than that in  a specimen of rigid H D  (B); (Case 3, 
grade 4). Neither is distinguishable from normal. Scale bar = 
200 wm. 
however, showed that there is no difference in striatal 
dopamine concentrations between patients with rigid 
HD and those with choreic HD [3l}, and Kurlan and 
colleagues showed normal levels of the dopamine me- 
tabolite homovanillic acid in the cerebrospinal fluid of 
patients who had rigid-kinetic HD [32]. These find- 
ings from neurochemical studies, coupled with our 
immunohistochemical data, indicate that nigrostriatal 
dopaminergic neurotransmission is probably normal in 
rigid HD. 
In conclusion, our findings indicate that the elevated 
striatal concentration of SS resulting from the persis- 
tence in HD of interneurons containing both SS and 
NPY is unlikely to be the cause of chorea in patients 
with HD. Furthermore, since tyrosine hydroxylase- 
immunoreactive neurons are apparently normal in 
number in patients with rigid-akinetic HD, it is un- 
likely that a dopamine deficiency accounts for the rigid- 
kinetic syndrome seen in these patients. Our findings 
in these brain specimens of rigid-kinetic HD are con- 
sistent with the hypothesis that chorea in HD results 
from selective loss of striatal neurons projecting to the 
GPe, and that rigidity results from loss of striatal 
neurons projecting to the GPe and those projecting to 
the GPi. Whether rigidity-akinesia would result from 
selective loss of striatal neurons projecting only to the 
GPi is an attractive but untested hypothesis. 
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